Considering Molecular Alterations As Pan-cancer Tissue-agnostic Targets

Overview

Journal Nat Cancer

Specialty Oncology

Date 2023 Dec 15

PMID 38102355

Authors

Jacob J Adashek

Shumei Kato

Jason K Sicklick

Scott M Lippman

Razelle Kurzrock

Affiliations

Soon will be listed here.

Citing Articles

Tumour-agnostic kinase inhibitors.

Adashek J, Nikanjam M, Kurzrock R Nat Rev Drug Discov. 2025; .

PMID: 40050521 DOI: 10.1038/s41573-025-01147-y.

If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.

Adashek J, Munoz J, Kurzrock R Med. 2024; 6(1):100550.

PMID: 39689708 PMC: 11725447. DOI: 10.1016/j.medj.2024.11.003.

Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors.

Lazar V, Raymond E, Magidi S, Bresson C, Wunder F, Berindan-Neagoe I Ther Adv Med Oncol. 2024; 16:17588359241289200.

PMID: 39429467 PMC: 11487509. DOI: 10.1177/17588359241289200.

If it's a target, it's a pan-cancer target: Tissue is not the issue.

Adashek J, Kato S, Sicklick J, Lippman S, Kurzrock R Cancer Treat Rev. 2024; 125:102721.

PMID: 38522181 PMC: 11093268. DOI: 10.1016/j.ctrv.2024.102721.

Forget lung, breast or prostate cancer: why tumour naming needs to change.

Andre F, Rassy E, Marabelle A, Michiels S, Besse B Nature. 2024; 626(7997):26-29.

PMID: 38347121 DOI: 10.1038/d41586-024-00216-3.

References

Tateo V, Marchese P, Mollica V, Massari F, Kurzrock R, Adashek J . Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel). 2023; 16(4). PMC: 10144220. DOI: 10.3390/ph16040614. View

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T . Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021; 39(4):273-284. PMC: 8078423. DOI: 10.1200/JCO.20.02088. View

Subbiah V, Wirth L, Kurzrock R, Pazdur R, Beaver J, Singh H . Accelerated approvals hit the target in precision oncology. Nat Med. 2022; 28(10):1976-1979. DOI: 10.1038/s41591-022-01984-z. View

Adashek J, Menta A, Reddy N, Desai A, Roszik J, Subbiah V . Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol Cancer Ther. 2022; 21(6):871-878. PMC: 9355618. DOI: 10.1158/1535-7163.MCT-21-0950. View

Westin J, Kurzrock R . It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther. 2012; 11(12):2549-55. PMC: 4107422. DOI: 10.1158/1535-7163.MCT-12-0473. View

Adashek J, Subbiah V, Kurzrock R . From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends Cancer. 2020; 7(1):15-28. DOI: 10.1016/j.trecan.2020.08.009. View

Drilon A, Laetsch T, Kummar S, Dubois S, Lassen U, Demetri G . Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8):731-739. PMC: 5857389. DOI: 10.1056/NEJMoa1714448. View

Tiacci E, Park J, De Carolis L, Chung S, Broccoli A, Scott S . Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015; 373(18):1733-47. PMC: 4811324. DOI: 10.1056/NEJMoa1506583. View

Marcus L, Lemery S, Keegan P, Pazdur R . FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019; 25(13):3753-3758. DOI: 10.1158/1078-0432.CCR-18-4070. View

10.

Corcoran R, Atreya C, Falchook G, Kwak E, Ryan D, Bendell J . Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015; 33(34):4023-31. PMC: 4669588. DOI: 10.1200/JCO.2015.63.2471. View

11.

Kumar K, Chen W, R Koduru P, Luu H . Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature. Am J Clin Pathol. 2015; 143(5):738-48. DOI: 10.1309/AJCPUD6W1JLQQMNA. View

12.

Pang Y, Yu G, Butler M, Sindiri S, Song Y, Wei J . Report of Canonical - Fusion in Glioblastoma. JCO Precis Oncol. 2021; 5. PMC: 8407655. DOI: 10.1200/PO.20.00519. View